Donald A. McGovern Jr. - Sep 4, 2023 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Donald A. McGovern, Jr.
Stock symbol
ATNF
Transactions as of
Sep 4, 2023
Transactions value $
$0
Form type
4
Date filed
9/6/2023, 07:28 PM
Previous filing
Jun 9, 2023
Next filing
Nov 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNF Common Stock Award $0 +25.2K +83.68% $0.00 55.3K Sep 4, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +15K $0.00 15K Sep 4, 2023 Common Stock 15K $0.67 Direct F2, F3
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +44.8K $0.00 44.8K Sep 4, 2023 Common Stock 44.8K $0.67 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued in consideration for serving on the Board of Directors, as Lead Director, Chairman of the Audit Committee, and as a Member of the Compensation Committee and of the Risk, Safety and Regulatory Committee of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2 Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F3 The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
F4 Granted in consideration for serving as Lead Director of the Company during 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.